Miriam Kim, MD
Assistant Professor, Medicine
- Email: email@example.com
Our goal is to develop more effective immunotherapies for acute myeloid leukemia (AML). We work at the interface of hematopoietic stem and progenitor cells (HSPCs) and T cells, as AML is a malignancy derived from HSPCs and still harbors many characteristics of its normal counterparts. We use chimeric antigen receptor (CAR) T cell therapy, in which T cells are genetically engineered to attack cancer, as this has achieved success in a variety of hematologic malignancies, such as B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia. We aim to extrapolate the success of CAR T cell therapy to AML.
Research keywords: CAR T cells; Hematopoietic stem cells; Cell and gene therapy
|Mentoring statement:||Not provided.|
|Some former postdocs’ career outcomes:||Not provided.|
Postdoc openings within the next year
|Number of postdoc positions:||1|
|Postdoc eligibility:||U.S. Citizens or Permanent Residents|
Current Visa-Holding Trainees in the U.S.
International Trainees Outside the U.S.